ReviewCells2026
The Elusive Origin of Glioblastoma: Where Do We Stand?
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains one of the most lethal cancers, and despite advancements in understanding its underlying molecular signature, effective therapeutics are still lacking. The multifaceted challenges of designing treatments for GBM are compounded by the inability to identify a definitive cell of origin, the understanding of which is crucial for developing impactful therapies and ultimately improving patient outcomes. High-resolution technologies, including single-cell and single-nucleus RNA sequencing, spatial transcriptomics, multi-omics, next generation glioma models, bioinformatics, and artificial intelligence are creating an important opportunity to comprehensively map the cellular origin of GBM and its evolutionary dynamics. Accumulating evidence support neural stem cells (NSCs) and oligodendrocyte precursor cells (OPCs) as primary candidates, providing critical insights into the ontogeny of GBM. This comprehensive review synthesizes current knowledge on the cellular origins of GBM and evaluates advanced methodologies, deepening our understanding of its development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.